Serigen closes a Pre-Series A Funding Round of Rs 10 Cr ($1.2M)
We’re thrilled to announce that Serigen has raised a Pre-Series A funding of Rs 10 Crore ($1.2M)! We feel privileged to receive the support of renowned and seasoned institutional investors like the IAN Alpha Fund and Colossa Ventures.
We also welcome our incoming angel investor Rahul Rathi and thank our existing angel investors for their steadfast belief in our vision for the company!
Serigen aims to establish its science-driven, IP-backed innovations in orthopaedics, advanced wound care, & soft tissue engineering as the global “Standard of Care” in tissue regeneration. Led by a stellar team of biomedical technology experts, Serigen is the world’s 1st company to successfully conduct a clinical trial using silk for bone repair. With this funding, we’re excited to embark on the next phase of our journey—demonstrating the clinical superiority of our world-class products & making them accessible to patients worldwide!
The proceeds of this funding will be directed towards the completion of clinical trials, obtaining Indian and global regulatory approvals for our product lines, accelerating sales and marketing efforts, and building and strengthening our team.
Media Coverage:
